Fintel reports that on March 28, 2025, Lake Street initiated coverage of OncoCyte (NasdaqCM:OCX) with a Buy recommendation.
Analyst Price Forecast Suggests 30.67% Upside
As of March 19, 2025, the average one-year price target for OncoCyte is $4.21/share. The forecasts range from a low of $4.04 to a high of $4.46. The average price target represents an increase of 30.67% from its latest reported closing price of $3.22 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for OncoCyte is 86MM, an increase of 4,471.77%. The projected annual non-GAAP EPS is -0.31.
What is the Fund Sentiment?
There are 41 funds or institutions reporting positions in OncoCyte. This is an increase of 6 owner(s) or 17.14% in the last quarter. Average portfolio weight of all funds dedicated to OCX is 0.16%, an increase of 129.74%. Total shares owned by institutions increased in the last three months by 18.65% to 8,539K shares.
What are Other Shareholders Doing?
Broadwood Capital holds 6,244K shares representing 21.83% ownership of the company. In its prior filing, the firm reported owning 4,929K shares , representing an increase of 21.06%. The firm increased its portfolio allocation in OCX by 7.76% over the last quarter.
AWM Investment holds 776K shares representing 2.71% ownership of the company. In its prior filing, the firm reported owning 1,097K shares , representing a decrease of 41.42%. The firm decreased its portfolio allocation in OCX by 40.63% over the last quarter.
Pura Vida Investments holds 654K shares representing 2.29% ownership of the company. In its prior filing, the firm reported owning 495K shares , representing an increase of 24.31%. The firm increased its portfolio allocation in OCX by 435.63% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 155K shares representing 0.54% ownership of the company. No change in the last quarter.
Geode Capital Management holds 137K shares representing 0.48% ownership of the company. In its prior filing, the firm reported owning 104K shares , representing an increase of 24.14%. The firm increased its portfolio allocation in OCX by 5.34% over the last quarter.
Oncocyte Background Information
(This description is provided by the company.)
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company's tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte has launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO™, the company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company previously announced its planned acquisition of Chronix Biomedical Inc. and its TheraSure™ CNI Monitor test, and also plans to continue with the development of DetermaMx™ as the Company seeks to expand into the blood-based monitoring market. Oncocyte's pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
